The final ruling has changed! Innovative Medical Management has revised its 2024 performance forecast, with the company accumulating losses of nearly 1.8 billion over six years | Interpretations

① Only a month after the performance forecast for 2024 was disclosed, Innovative Medical Management has revised its performance forecast, with net losses expanding to 0.1 billion yuan - -85 million yuan; ② Innovative Medical Management had made relevant risk warnings in its performance forecast, and the dispute case between Qianhai Excellence and Jianhua Hospital has been heard but not yet ruled; ③ Since 2019, Innovative Medical Management has reported losses for six consecutive years, with a cumulative loss amounting to nearly 1.8 billion yuan.

cls.cnFeb 25 09:10 ET

Targeting the original controlling shareholder Zhong Zhu Group, Zhong Zhu Healthcare Holding initiates multiple lawsuits | Quick read announcement

① This evening, Zhong Zhu Healthcare Holding announced three litigation cases, with a total amount involved of 0.219 billion yuan. ② Since January 22 of this year, there have been six lawsuits in which Zhong Zhu Healthcare Holding has been the plaintiff, related to the company's previous Equity Transfer agreement. ③ The company's former controlling shareholder, Zhong Zhu Group, can be seen in the defendant's seat.

cls.cnFeb 17 09:49 ET

Huawei will release AI pathology models, and the Medical Industry is迎来 an important opportunity for intelligent upgrades.

① Huawei's data storage public account released information stating that it will launch the Ruijin pathological model based on the Huawei DCS AI solution. ② Jianghai Securities pointed out that under the guidance of the Health China 2030 Global Strategy, the Medical Industry is ushering in an important opportunity for intelligent upgrades.

cls.cnFeb 13 19:04 ET

Bid Medicine disclosed a "three-step" acquisition plan: specific transaction prices are not determined, planning to raise funds through a private placement.

① Regarding the purpose of the Trade, Bid Medicine stated that it can further improve Overseas sales channels, enhance the diversity of company products, and optimize the efficiency of the Global supply chain and warehousing Operation; ② Combi's Net income in the past two years was 22.0418 million USD and 20.4237 million USD. After the Trade is completed, Combi will be included in the management and consolidation scope of Bid Medicine.

cls.cnJan 27 08:06 ET

WUXI XDC's net income for 2024 is expected to increase by 260%. WUXI APPTEC recently cashed out 2.4 billion Hong Kong dollars at a high point | Quick read of the announcement.

In 2024, WUXI XDC expects total revenues, Net income, and adjusted Net income to grow by over 85%, 260%, and 170% year-on-year, respectively; According to the latest data from Frost & Sullivan, it is projected that by 2030, the Global market size for ADC and XDC will reach 66.2 billion US dollars.

cls.cnJan 15 00:06 ET

Bid Medicine plans to implement acquisitions in three steps to indirectly acquire 100% equity of a pharmaceutical molecular block company.

① Combi-Blocks, Inc.'s main distributor in China is Allen Chemical, and its sales team representatives indicated that the agency price should not change for now. ② Regarding the reasons for this acquisition, Bid Pharmaceutical explained that it mainly aims to enhance the competitiveness of its core business, increase market share and position, strengthen product diversity, and create a coordinated effect with the existing business of the listed company, bringing new momentum to overseas business.

cls.cnJan 13 22:04 ET